#United States #Caris Life Sciences #Irving #Colorectal Cancer #DPYD Testing

Caris Life Sciences and Colorectal Cancer Awareness

In March, Caris Life Sciences, an innovator in precision medicine using next-generation AI technology, underscores the importance of DPYD testing for colorectal cancer during Colorectal Cancer Awareness Month. This initiative not only aims to raise awareness but also to emphasize how DPYD testing can significantly influence treatment strategies for patients diagnosed with this prevalent cancer.

Colorectal cancer is a leading cause of cancer-related mortality, with a worrying trend of increased diagnoses among younger adults. Recent statistics released by the American Cancer Society have brought attention to this disturbing rise, calling for enhanced strategies in early detection and personalized treatment approaches. The instances of colorectal cancer being diagnosed at an earlier age highlight the critical need for more proactive measures concerning screening and genetic testing, which can guide treatment choices that align with an individual's genetic profile.

Among the therapeutic options available for colorectal cancer, fluoropyrimidine-based treatments like capecitabine and fluorouracil play a significant role. However, genetic factors can influence patient responses to these therapies. Specifically, variations in the DPYD gene can reduce the activity of the enzyme dihydropyrimidine dehydrogenase (DPD), leading to severe adverse reactions and increased toxicity from these common drugs. Recognizing this danger, the FDA has modified safety guidelines for capecitabine and 5-FU, recommending genetic testing for DPYD variants before treatment is initiated, barring urgent care situations.

Despite this guidance, discrepancies in the implementation of DPYD testing exist across various healthcare settings. Many patients and healthcare providers remain unaware of the importance of identifying these genetic factors that can drastically change treatment outcomes. To bridge this gap, Caris Life Sciences has integrated DPYD reporting into its Caris Assure platform. This blood-based molecular profiling assay, utilizing Whole Exome and Whole Transcriptome Sequencing, enables clinicians to evaluate tumor biomarkers alongside inherited genetic variants from one single blood draw. This comprehensive approach not only enhances patient care but also equips providers with critical information prior to commencing treatment.

David Spetzler, President of Caris, emphasizes that “in precision oncology, effective treatment decisions hinge on understanding both the potential benefits and the risks connected to therapies.” During Colorectal Cancer Awareness Month, he stresses the significance of DPYD testing as a vital tool that can guide clinicians in selecting the most appropriate and safest treatment for individuals considering fluoropyrimidine therapies.

As the cancer care landscape shifts towards more individualized treatment strategies, acknowledging the influence of pharmacogenomics like DPYD status is essential in the discourse on precision medicine. Enhancing education surrounding biomarker-informed care is crucial, not only for improving treatment planning but also for elevating the overall experience of patients navigating their cancer treatment journeys.

About Caris Life Sciences
Caris Life Sciences stands at the forefront of precision medicine, bringing innovative solutions to transform healthcare through robust molecular profiling. Their extensive suite of services, including Whole Genome, Whole Exome, and Whole Transcriptome Sequencing, paired with advanced AI and machine learning capabilities, ensures patients receive tailored treatments based on their genetic makeup and tumor characteristics. Headquartered in Irving, Texas, Caris is poised to revolutionize the healthcare landscape with its multidimensional approach to diagnostics and treatment optimization.,